OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
June 02, 2023
An increase in applications for gene therapies is putting stress on FDA’s resources.
May 31, 2023
The start of production of US engineering batches of NXC-201, a CAR-T cell therapy candidate in early clinical development, is the first step in transferring Nexcella’s existing manufacturing process to the United States.
Sandoz’s marketing authorization applications for a proposed biosimilar to denosumab are supported by a comprehensive analytical and clinical data package.
May 23, 2023
With $73 million in financing from investment firms, Myeloid Therapeutics plans to accelerate its lead clinical candidate into Phase I/II development for treating solid tumors.
May 18, 2023
Sania Therapeutics has emerged from stealth mode and launched its technology platforms for enabling the development of novel therapeutics to treat neural circuit dysfunction.
May 16, 2023
Under the collaboration, BiOneCure Therapeutics and Nanjing Leads Biolabs intend to develop a range of innovative antibody-drug conjugates for treating solid tumors.
May 03, 2023
The development of CAR-T therapies for solid tumor cancers presents a myriad of challenges.
April 15, 2023
Lipids aren’t the only important ingredients influencing stability and in vivo performance.
The recent success of mRNA vaccines has opened the door for further and future development of nucleic acid-based therapies.
Actions combatting the next pandemic must be diverse, reliable, and sustainable.